FibroGen: Growth Prospects Are Not Worth Current Valuations (NASDAQ:FGEN)

Amid strong headwinds, FibroGen has achieved a high market valuation. Click here to read my analysis on why I think investors should avoid FGEN stock.

Related Keywords

China ,California ,United States ,Ukraine ,San Francisco ,Vladimir Agapov ,Fibrogen Inc ,Astellas Pharma Inc ,Pipeline Of Treatments Under Development ,Drug Administrationa Rare Pediatric Disease Designation ,Drug Administration ,Nasdaq ,Strong Headwinds ,Has Achieved ,High Market ,The Biotechnology ,Treatments Under ,Fast Track ,Rare Pediatric Disease Designation ,Pediatric Rare Disease ,Astellas Pharma ,Conditions Targeted ,